TABLE 1

Recommended Seasonal Influenza Vaccines for Different Age Groups: United States, 2013–2014 Influenza Season

VaccineTrade NameManufacturerPresentationThimerosal Mercury ContentaAge Group
Inactivated
 IIV3FluzoneSanofi Pasteur0.25-mL prefilled syringe       06–35 mo
0.5-mL prefilled syringe       0≥36 mo
0.5-mL vial       0≥36 mo
5.0-mL multidose vial       25≥6 mo
 IIV3Fluzone IntradermalSanofi Pasteur0.1-mL prefilled microinjection       018–64 y
 IIV3Fluzone HDSanofi Pasteur0.5-mL prefilled syringe       0≥65 y
 IIV3FluvirinNovartis0.5-mL prefilled syringe       ≤1.0≥4 y
5.0-mL multidose vial       25≥4 y
 IIV3AgrifluNovartis0.5-mL prefilled syringe       0≥18 y
 IIV3FluarixGlaxoSmithKline0.5-mL prefilled syringe       0≥36 mo
 IIV3FluLavalID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)5.0-mL multidose vial       25≥3 y
 IIV3AfluriaCSL Biotherapies (distributed by Merck)0.5-mL prefilled syringe       0≥9 yb
5-mL multidose vial       24.5≥9 yb
 ccIIV3FlucelvaxNovartis Vaccines0.5-mL prefilled syringe       0≥18 y
 IIV4Fluzone QuadrivalentSanofi Pasteur0.25-mL prefilled syringe       06-35 mo
0.5-mL prefilled syringe       0≥36 mo
0.5-mL vial       0≥36 mo
 IIV4Fluarix QuadrivalentGlaxoSmithKline0.5-mL prefilled syringe       0≥36 mo
 IIV4FluLaval QuadrivalentID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)5.0-mL multidose vial       25≥3 y
Recombinant
 RIV3FluBlokProtein Sciences0.5-mL vial       018–49 y
Live-attenuated
 LAIV4FluMist QuadrivalentMedImmune0.2-mL sprayer       02–49 y
  • Data sources: American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2012–2013. Pediatrics. 2012;130(4):780–792; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2012–13 influenza season. MMWR Morb Mortal Wkly Rep. 2012;61(32):613–618; and Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: interim recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. MMWR Morb Mortal Wkly Rep. 2013;62(18):356.

  • a Microgram of Hg/0.5-mL dose.

  • b Age indication per package insert is ≥5 y; however, the Advisory Committee on Immunization Practices recommends Afluria not be used in children 6 months through 8 years of age because of increased reports of febrile reactions noted in this age group. If no other age-appropriate, licensed, inactivated seasonal influenza vaccine is available for a child 5 through 8 years of age who has a medical condition that increases the child’s risk of influenza complications, Afluria can be used; however, pediatricians should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine.